In its third quarter report released October 30, 2025, Kimberly-Clark delivered adjusted EPS of $1.82, $0.07 ahead of consensus estimates, and posted revenue of $4.15 billion, exceeding forecasts by $50 million and holding flat year-over-year despite a 2.2% headwind from exiting the private-label diaper business in the U.S. Organic sales grew 2.5%, driven by a 2.4% volume increase, while portfolio mix and pricing were neutral. Adjusted gross margin stood at 36.8%, down 170 basis points, as productivity gains were offset by higher input costs including tariffs and reinvestment in pricing initiatives.

Operating in 175 countries through two segments—Personal Care (Huggies, Kotex, Depend) and Consumer Tissue (Kleenex, Scott, Cottonelle)—Kimberly-Clark generates approximately $20 billion in annual revenue. Its diversified portfolio and scale provide pricing power in key markets, underpinning predictable cash flow generation and supporting ongoing investment in innovation, marketing and supply-chain optimization across high-growth regions such as Latin America and Asia.

The company’s planned acquisition of Kenvue, valued at $48.7 billion in a cash-and-stock transaction, represents a strategic expansion into consumer health and personal care products. This bolt-on deal adds leading brands in over-the-counter remedies and skincare to Kimberly-Clark’s portfolio, with management expecting annual cost and tax synergies of roughly $500 million to materialize by 2027 and to accelerate margin expansion over the medium term.

With 53 consecutive years of dividend increases, Kimberly-Clark is a member of the elite Dividend Kings. The company’s current dividend yield stands at approximately 5.1%, significantly above the S&P 500 average, and its conservative payout ratio—typically in the mid-60% range—provides ample flexibility to sustain distributions even in a downturn, making KMB a core holding for long-term income portfolios.